Driving the UK’s “innovation engine” for novel AMR therapeutics
Despite the UK having “a very healthy” therapeutic pipeline, more needs to be done in the fight against antimicrobial resistance (AMR), NovaBiotics’ CEO asserts.
List view / Grid view
Despite the UK having “a very healthy” therapeutic pipeline, more needs to be done in the fight against antimicrobial resistance (AMR), NovaBiotics’ CEO asserts.
5 February 2016 | By Victoria White
NovaBiotics was awarded the Life Science Investment of the Year Award at the Scottish Enterprise Life Sciences Annual Awards...